At ACE BioSciences, we use proteomics-led target identification and focussed target validation, to find novel drug targets within a wide range of diseases. Our technology is ideally suited for creating a wide variety of drugs that protect against important illnesses that are endemic to many parts of the world.

IP strategy
Our technological platform forms the basis for a strong IP position. Only those targets for which no prior art IP exists are selected to enter evaluation in the target validation process. We have generated a robust intellectual property portfolio.